IthaID: 560
Names and Sequences
| Functionality: | Globin gene causative mutation | Pathogenicity: | Benign / Likely Benign |
|---|---|---|---|
| Common Name: | CD 54 CAG>CGG [Gln>Arg] | HGVS Name: | HBA1:c.164A>G |
| Hb Name: | Hb Shimonoseki | Protein Info: | α2 54(E3) Gln>Arg |
Context nucleotide sequence:
ACTTCGACCTGAGCCACGGCTCTGCCC [A/G] GGTTAAGGGCCACGGCAAGAAGGTGG (Strand: +)
Protein sequence:
MVLSPADKTNVKAAWGKVGAHAGEYGAEALERMFLSFPTTKTYFPHFDLSHGSARVKGHGKKVADALTNAVAHVDDMPNALSALSDLHAHKLRVDPVNFKLLSHCLLVTLAAHLPAEFTPAVHASLDKFLASVSTVLTSKYR
Also known as: Hb Hikoshima
We follow the HGVS sequence variant nomenclature and IUPAC standards.
Phenotype
| Hemoglobinopathy Group: | Structural Haemoglobinopathy |
|---|---|
| Hemoglobinopathy Subgroup: | α-chain variant |
| Allele Phenotype: | N/A |
| Stability: | N/A |
| Oxygen Affinity: | N/A |
| Associated Phenotypes: | N/A |
Location
| Chromosome: | 16 |
|---|---|
| Locus: | NG_000006.1 |
| Locus Location: | 37860 |
| Size: | 1 bp |
| Located at: | α2, α1 |
| Specific Location: | Exon 2 |
Other details
| Type of Mutation: | Point-Mutation(Substitution) |
|---|---|
| Effect on Gene/Protein Function: | Missense codons (Protein Structure) |
| Ethnic Origin: | Japanese, Greek |
| Molecular mechanism: | N/A |
| Inheritance: | Recessive |
| DNA Sequence Determined: | Yes |
HPLC
Disclaimer: The HPLC images are provided as an information resource only.
Bio-Rad Laboratories, Inc and the ITHANET Portal disclaim responsibility and have no liability if this information is used for diagnostic or treatment purposes.
D-10™ and VARIANT™ are registered trademarks of Bio-Rad Laboratories, Inc. and used with permission.
Redistribution and use of the above material is allowed only with permission by Bio-Rad Laboratories, Inc.
To access HPLC images and reports for different variants, use the IthaChrom tool.
| ID | Hb Variant | Gene | Instrument | Method | Area (%) | Ret Time (min) | Comments | ||
|---|---|---|---|---|---|---|---|---|---|
| 161 | Hb Shimonoseki | α2 | D-10 | Dual Kit Program | 14.7 | 4.17 | Heterozygous. Elutes as HbS. | [PDF] | |
| 161 | Hb Shimonoseki | α1 | D-10 | Dual Kit Program | 14.7 | 4.17 | Heterozygous. Elutes as HbS. | [PDF] | |
| 162 | Hb Shimonoseki | α2 | VARIANT | β-thal Short Program | 14.5 | 4.21 | Heterozygous. Elutes as HbS. | [PDF] | |
| 162 | Hb Shimonoseki | α1 | VARIANT | β-thal Short Program | 14.5 | 4.21 | Heterozygous. Elutes as HbS. | [PDF] |
In silico pathogenicity prediction
Publications / Origin
- HANADA M, RUCKNAGEL DL, The abnormality of the primary structure of hemoglobin Shimonoseki., Biochem. Biophys. Res. Commun. , 11(0), 229-38, 1963
- MIYAJI T, IUCHI I, TAKEDA I, SHIBATA S, HEMOGLOBIN SHIMOSEKI (ALPHA-2-53ARG BETA-2-A), A SLOW-MOVING HEMOGLOBIN FOUND IN A JAPANESE FAMILY, WITH SPECIAL REFERENCE TO ITS CHEMISTRY., Nippon Ketsueki Gakkai Zasshi , 26(0), 531-7, 1963
- HANADA M, RUCKNAGEL DL, THE CHARACTERIZATION OF HEMOGLOBIN SHIMONOSEKI., Blood , 24(0), 624-35, 1964
- Imai K, Morimoto H, Kotani M, Shibata S, Miyaji T, Studies on the function of abnormal hemoglobins. II. Oxygen equilibrium of abnormal hemoglobins: Shimonoseki, Ube II, Hikari, Gifu, and Agenogi., Biochimica et biophysica acta, 200(2), 197-202, 1970
- Theodoridou S, Delaki E, Skatharoudi E, Karakasidou O, Vyzantiadis TA, Theodoridis T, Chalkia P, First Report of a Coincidental Discovery of Hb Shimonoseki [α54(E3)Gln→Arg, HBA2: c.164A > G (or HBA1)] in a Greek Family., Hemoglobin, 42(4), 281-282, 2018
- Sharma P, Bhatia P, Das R, Chhabra S, Hira JK, Hemoglobin Shimonoseki :c.164A > G Illustrating the Continuing Utility of the Sickling Test and the Challenges in Antenatal Genetic Counselling., Indian J Hematol Blood Transfus, 40(1), 166-168, 2024
Created on 2010-06-16 16:13:15,
Last reviewed on 2024-03-11 13:26:46 (Show full history)
Disclaimer: The information on this website is provided as an information resource only
and must not to be used as a substitute for professional diagnosis and treatment.
The ITHANET Portal and IthaGenes are not responsible or liable for any advice, course of treatment,
diagnosis or any other information, services or products that an individual obtains through this website.